Clinical Trial Support
Oxford University and Hospitals Trust hosts one of the largest, most successful and respected cancer research communities in Europe, spanning a range of biological, physical and medical expertise. To ensure discoveries and advances are efficiently translated into patient benefit, Oxford Cancer supports adaptable core clinical trial infrastructure. This facility is flexible and responsive to enable scientists from a range of clinical and fundamental scientific backgrounds to translate their work into the clinic.
Funding of core capacity at the Oncology Clinical Trials Office (OCTO) and the Early Phase Clinical Trials Unit (EPCTU) provides researchers and collaborators from any discipline, department or institute across both the University and Trust access to all the regulatory, administrative, statistical, and clinical skillsets and support needed to help you develop and deliver national or international early phase trials in which their discoveries are evaluated in the clinical setting.
Check out the Oxford cancer clinical trials webpage here for more information.
WHERE WE CAN HELP
All Oxford Cancer members are eligible to apply and access the opportunity to present their project at the interactive Clinical Trial Development Group (CTDG).
The CTDG is an informal forum of clinicians, statisticians, trial managers, pathologists, and lab scientists who will help you to refine your project and develop trial proposals, signpost opportunities for collaboration and/or translational research, and identify relevant funding calls. Through this approach, Oxford Cancer is able to maintain an active pipeline of trials which realise the patient benefit of research across Oxford.
We are always looking for new and impactful discoveries to develop, and we encourage all interested researchers to contact Oxford Cancer if they are interested in utilising this infrastructure. You don’t have to have a full trial proposal ready or be an experienced clinical investigator to bring an idea to CTDG. As a guide we suggest contacting Sarah Pearson (OCTO Trial Management Director) or Fiona Cooper (OCTO Administrator) to have a preliminary conversation.
|Grant Application/Funding||Regulatory reporting||Patient/Subject Recruitment|
|Protocol Development||Risk Assessment||IMP/Drug Supplies|
|Regulatory/MHRA Approval||Data Management||Trial Master File|
|Pharmacovigilance||eCRFs||Compliant I.T. Systems|
|Safety||Sample Collection||CRO Management|
|Contracts||Stakeholder reporting||NHS Site Management|
|Imaging||Radiation Therapy||First in Man Therapeutics|
|Intratumoral Injection||Device Approval|
Oxford Clinical Trials
A follow-on clinical trial investigating antimalarial drug Atovaquone as a method to improve the impact of chemoradiotherapy
A multi-disciplinary clinical trial and research project investigating new immunotherapy drug opportunities in oesophageal cancer.
MAGE Cancer Vaccine (VTP-600)
A novel cancer immunotherapy vaccine based on new & unique surface molecules that Oxford researchers have discovered.
An observational cohort study to identify early detection markers for malignant blood cancers such as CLL and MGUS
The SYMPLIFY study will evaluate the revolutionary multi-cancer blood test Galleri, for future implementation in the NHS.